The Medicines Patent Pool Announces First Licence for Tuberculosis Treatment

The Medicines Patent Pool, 25 January 2017

Read online at:

The Medicines Patent Pool today announced that it has signed a licence with Johns Hopkins University to facilitate the clinical development of tuberculosis (TB) drug candidate sutezolid. The antibiotic sutezolid has long been considered a promising investigational treatment that, if further developed in combination with other drugs, could be used to more effectively treat both drug-sensitive and drug-resistant TB in patients. Faster acting, better therapies to treat TB are a particularly urgent global public health priority. With the exception of two new drugs that have come to market recently, the dearth of new alternatives to decades-old TB drugs contributes to our limited response to the epidemic.

(Visited 19 times, 1 visits today)
This entry was posted in Essential Medicines, General, Tuberculosis. Bookmark the permalink.